Sugi Predict

Sugi Predict / Targets / RBBP4

RBBP4

Histone-binding protein RBBP4 · Q09028 · RBBP4 on Sugi Atlas →

16,322 patent compounds predicted against RBBP4, 11,330 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2593163 SCHEMBL2593163 0.58 8/20
SCHEMBL989559 SCHEMBL989559 0.32 8/20
SCHEMBL2586392 SCHEMBL2586392 0.54 7/20
SCHEMBL1695610 SCHEMBL1695610 0.54 7/20
SCHEMBL2593063 SCHEMBL2593063 0.53 7/20
SCHEMBL2594034 SCHEMBL2594034 0.49 7/20
SCHEMBL2591826 SCHEMBL2591826 0.66 6/20
SCHEMBL2594666 SCHEMBL2594666 0.47 6/20
SCHEMBL2594593 SCHEMBL2594593 0.47 6/20
SCHEMBL2590937 SCHEMBL2590937 0.47 6/20
SCHEMBL2588380 SCHEMBL2588380 0.81 5/20
SCHEMBL2594078 SCHEMBL2594078 0.79 5/20
SCHEMBL2595147 SCHEMBL2595147 0.67 5/20
SCHEMBL2589109 SCHEMBL2589109 0.65 5/20
SCHEMBL2586263 SCHEMBL2586263 0.62 5/20
SCHEMBL2595059 SCHEMBL2595059 0.56 5/20
SCHEMBL2590054 SCHEMBL2590054 0.55 5/20
SCHEMBL1694628 SCHEMBL1694628 0.53 5/20
SCHEMBL2593740 SCHEMBL2593740 0.53 5/20
SCHEMBL2592178 SCHEMBL2592178 0.53 5/20

Clinical trials — most relevant to RBBP4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
Vorinostat in Children PHASE1/PHASE2COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma PHASE2COMPLETED
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) PHASE1/PHASE2COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma PHASE1COMPLETED
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma EARLY_PHASE1RECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Profiles of Expression in HPV+ Versus HPV Head and Neck Cancers nanUNKNOWN
Study of Proteins in Head and Neck Cancer Cells nanCOMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
New Biomarkers for Diagnosis and Follow-up of Patients With LRBA or CTLA4 Deficiencies nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics nanCOMPLETED
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a RBBP4 binder may also engage these)

ProteinNameSimilarity
Q3MHL3 — 1.000 Q3MHL3 →
Q9W7I5 — 1.000 Q9W7I5 →
Q5RF92 — 1.000 Q5RF92 →
Q5M7K4 — 1.000 Q5M7K4 →
Q60972 — 1.000 Q60972 →
Q6P3H7 — 1.000 Q6P3H7 →
Q6INH0 — 0.992 Q6INH0 →
O93377 — 0.991 O93377 →
Q7ZTY4 — 0.972 Q7ZTY4 →
Q8AVH1 — 0.970 Q8AVH1 →
Q6P315 — 0.960 Q6P315 →
Q24572 — 0.939 Q24572 →
Q498M4 — 0.932 Q498M4 →
P61965 — 0.932 P61965 →
Q2KIG2 — 0.931 Q2KIG2 →
RBBP7 Histone-binding protein RBBP7 0.929 landscape →
WDR5 WD repeat-containing protein 5 0.928 landscape →
Q9I8G9 — 0.928 Q9I8G9 →
Q5M786 — 0.926 Q5M786 →
Q60973 — 0.923 Q60973 →
Q71UF4 — 0.923 Q71UF4 →
Q4R304 — 0.923 Q4R304 →
P61220 — 0.921 P61220 →
Q5RFF4 — 0.921 Q5RFF4 →
P41567 — 0.921 P41567 →
Q5E938 — 0.919 Q5E938 →
Q99LG2 — 0.918 Q99LG2 →
Q9CXU9 — 0.917 Q9CXU9 →
Q4R4X9 — 0.917 Q4R4X9 →
O60739 — 0.917 O60739 →